OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

SANOFI/  FR0000120578  /

Turquoise
2024-06-11  5:29:54 PM Chg. -0.18 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
90.01EUR -0.20% 82,570
Turnover: 7.45 mill.		 -Bid Size: - -Ask Size: - 112.69 bill.EUR 4.18% 20.86
GlobeNewswire 06-11 Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Ha...
GlobeNewswire 06-11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 06-03 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...
GlobeNewswire 05-31 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
GlobeNewswire 05-31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 05-31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire 05-31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 05-31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire 05-30 Press Release: Sanofi completes acquisition of Inhibrx, Inc.
GlobeNewswire 05-27 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...
GlobeNewswire 05-23 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
GlobeNewswire 05-21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 05-20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire 05-13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
TeleTrader 05-10 Novavax skyrockets 213.5% in premarket, highest in 16 months
TeleTrader 05-10 Novavax soars 39.6% in premarket after Sanofi license deal
GlobeNewswire 05-10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
TeleTrader 05-09 Europe opens mixed with BoE in focus
GlobeNewswire 05-08 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 05-07 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights